The nephrotoxic potentials of the new aminoglycoside SCH 21420 and amikacin were compared in a rat model. Groups of rats received 100, 200, 300, or 600 mg of either drug per kg per day for 14 days. Enzymuria, urine osmolality, protein excretion, and blood urea nitrogen were monitored at periodic intervals, whereas creatinine clearance and pathological changes were determined at sacrifice. Amikacin caused more enzymuria at the two lower doses as well as greater proteinuria and blood urea nitrogen elevations at the highest dose than did SCH 21420 (P < 0.05). Pathological changes were more severe with amikacin than with SCH 21420 at the three lower doses (P < 0.05); however, at the 600 mg/kg per day dose, the pathological scores and creatinine clearances of animals receiving either drug were not significantly different (P > 0.05).
Aminoglycosides are very useful antibiotics in the treatment of patients with life-threatening bacterial infections. However, their nephrotoxic potential continues to concern clinicians (1). SCH 21420, a new derivative of gentamicin B, has in vitro bactericidal activity which compares favorably with currently available aminoglycosides (4, 12) . The proposed dose for man is the same as amikacin, 15 mg/kg per day (I. Tabachnick, Schering Corp., personal communication). To compare the relative nephrotoxicities of SCH 21420 and amikacin, we studied the functional and structural effects of both drugs upon the kidney in rats.
MATERIALS AND METHODS
Adult male Sprague Dawley rats (Cox Laboratories, Indianapolis, Ind.), weighing 225 to 250 g, were housed singly in metabolic cages, fed standard Purina Rat Chow ad libitum, and allowed free access to water. Twenty-four-hour urine specimens were collected under mineral oil to prevent evaporation.
The rats were randomly assigned to 11 groups of 10 rats each. Four groups received SCH 21420 at doses of 100, 200, 300, and 600 mg/kg per day. Four groups received the same doses of amikacin. These doses are equivalent to 1, 2, 3, and 6 times the recommended dose in humans when adjusted for surface area. Two groups received saline diluent and one group received no injections.
On the day before the first injection day (day 0), day 7, and day 14, 24-h urine specimens were collected. Volume, osmolality, protein, n-acetylglucosaminidase, and creatinine concentrations were measured. Blood was obtained from the tail for blood urea nitrogen (BUN) determination. On the day of sacrifice (day 15), creatinine was measured in serum and urine for the calculation of creatinine clearance. Kidneys from each animal were weighed and prepared for light microscopy by standard techniques (5) . Histological changes were graded as follows by a pathologist unaware of the regimens: grade 0, normal; grade 1, cloudy swelling of proximal tubular epithelium without necrosis; grade 2, necrosis and/or regeneration of 25% of the cortical area; grade 3, necrosis and/or regeneration of 25% but <50% of the cortical area; grade 4, necrosis and/or regeneration of 50% but <75% of the cortical area; and grade 5, necrosis of >75% of the cortical area.
Creatinine was measured by an automated technique (AutoAnalyzer, Chauncey, N.Y.). BUN was measured by the method of March et al. (7), and nacetylglucosaminidase was measured by the technique of Patel et al. (8) . Protein was measured by the Coomassie blue dye reaction (2) and expressed as excretion per milligram of creatinine. Urine osmolality was determined by freezing-point depression. Statistical comparisons were performed by one-way analysis of variance. Where differences were shown, Duncan's multiple range statistic was used for comparisons. Since the saline injected and noninjected groups were not significantly different, data from these groups were pooled. Ninety-five percent confidence limits were accepted as significant.
RESULTS
Changes in the variables monitored are displayed in Fig. 1 . The excretion of n-acetylglucosaminidase was the most sensitive indicator of nephrotoxicity. After 2 weeks of therapy, significant enzymuria compared to controls was observed at all four doses of amikacin and the three higher doses of SCH 21420 (P < 0.05).
Urinary protein excretion was significantly increased in a dose-related fashion after 7 (3, 6) . Generally, these differences are observed when the drugs are administered at high doses (6) . However, comparison of the doses in the rat with the recommended dose in humans should be made using surface area adjustments. On that basis, the dosages used in this study were 1, 2, 3, and 6 times the human dose. The relevance of the higher doses to the clinical use of aminoglycosides in man is not entirely clear. Although gentamicin appears more nephrotoxic than either amikacin or tobramycin in rats (3, 6) , double-blind prospective protocols in man suggest that these drugs are similar in their nephrotoxic potential (10, 11) . Nevertheless, more subtle differences, requiring larger numbers of subjects to be demonstrable, may indeed exist.
The results of the present study indicate that SCH 21420 and amikacin differ in their nephrotoxic potential. At The data suggest that SCH 21420 compares favorably to amikacin with respect to its nephrotoxic potential at lower doses in the rat. SCH 21420 may exhibit a dose-response nephrotoxicity relationship which is initially less steep than amikacin. SCH 21420 does, however, cause functional and structural renal injury typical for this class of antimicrobial agents. Since SCH 21420 compares favorably to amikacin with respect to in vitro activity against many aerobic gram-negative bacilli and Staphylococcus aureus (4, 9, 12) and also exhibits documented synergism with penicillin against enterococci (9), it appears that SCH 21420 may be a valuable addition to the aminoglycoside armamentarium.
